05:39 PM EDT, 03/14/2024 (MT Newswires) -- Geron ( GERN ) said Thursday the US Food and Drug Administration's Oncologic Drugs Advisory Committee voted in favor of the benefit-to-risk profile of imetelstat.

The vote was 12-2, and the target action date for the company's new drug application is June 16, Geron ( GERN ) said.

The company is seeking authorization for imetelstat for the treatment of transfusion-dependent anemia in certain patients with lower-risk myelodysplastic syndromes.